Benech Nicolas, Chaffringeon Lorenzo, Briot Thomas, Kolenda Camille, Pirot Fabrice, Laurent Frédéric, Ferry Tristan
Hospices civils de Lyon, France - Université Claude Bernard Lyon 1, France - Tumor Escape Resistance and Immunity Department, Cancer Research Center of Lyon (CRCL), Inserm U1052, CNRS UMR 5286, Lyon, France.
Hospices civils de Lyon, France - Centre international de recherche en infectiologie (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France.
Med Sci (Paris). 2022 Dec;38(12):1043-1051. doi: 10.1051/medsci/2022169. Epub 2022 Dec 13.
Bacteriophages are naturally occurring viruses that specifically target bacteria. They are widely distributed in the environment. The concept of phage therapy is to isolate phages, characterize them, cultivate them and then purify them to treat bacterial infections. There is currently a revival of phage therapy, and its implementation presupposes the availability of active phages of pharmaceutical quality. From a regulatory point of view, the status of phages is not yet clearly defined by the authorities. The availability of phages produced by the pharmaceutical industry and through academic development programs such as the PHAGEinLYON program represents a breakthrough in the development of phage therapy. Prosthetic joint infections and digestive diseases seem to be relevant indications, but preclinical studies and randomized clinical trials are now needed to be done.
噬菌体是天然存在的、专门靶向细菌的病毒。它们广泛分布于环境中。噬菌体疗法的概念是分离噬菌体、对其进行表征、培养然后纯化以治疗细菌感染。目前噬菌体疗法正在复兴,其实施前提是要有具备药物质量的活性噬菌体。从监管角度来看,当局尚未明确界定噬菌体的地位。制药行业以及通过诸如PHAGEinLYON项目等学术开发项目生产的噬菌体,为噬菌体疗法的发展带来了突破。人工关节感染和消化系统疾病似乎是相关适应症,但目前还需要开展临床前研究和随机临床试验。